7-methoxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid ethyl ester | 108048-57-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 7-methoxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid ethyl ester
• 英文别名: Ethyl 7-methoxy-1,2,3,4-tetrahydro-2-naphthalenecarboxylate；ethyl 7-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate
• CAS: 108048-57-3
• 化学式: C₁₄H₁₈O₃
• 分子量: 234.295
• InChiKey: URRCBLGXCFTNSR-UHFFFAOYSA-N

物化性质

• 沸点：
  339.5±42.0 °C(Predicted)
• 密度：
  1.092±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-methoxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid ethyl ester 在 四溴化碳 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 14.0h， 生成 3-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)methylamino]propan-1-ol
  参考文献：
  名称：

  New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D₂ Agonist Pharmacophore. Structure−Activity Relationships of a Series of 2-(Aminomethyl)chromans

  摘要：

  A series of 2-(aminomethyl)chromans (2-AMCs) was synthesized and evaluated for their affinity and selectivity for both the high-and low-affinity agonist states (D-2(High) and D-2(Low), respectively) of the dopamine (DA) D-2 receptor. The 7-hydroxy-2-(aminomethyl)chroman moiety was observed to be the primary D-2 agonist pharmacophore. The 2-methylchroman moiety was discovered to be an entirely novel scaffold which could be used to access the D-2 agonist pharmacophore. Attaching various simple alkyl and arylalkyl side chains to the 7-hydroxy 2-AMC nucleus had significant effects on selectivity for the D-2(High) receptor vs the 5HT(1A) and alpha(1) receptors. A novel DA partial agonist, (R)-(-)-2-(benzylamino)methyl)chroman-7-ol [R-(-)-35c], was identified as having the highest affinity and best selectivity for the D-2(High) receptor vs the alpha(1) and 5HT(1A) receptors. Several regions of the 2-AMC nucleus were modified and recognized as potential sites to modulate the level of intrinsic activity. The global minimum conformer of the 7-hydroxy-2-AMC moiety was identified as fulfilling the McDermed model D-2 agonist pharmacophoric criteria and was proposed as the D-2 receptor-bound conformation. Structure-activity relationships gained from these studies have aided in the synthesis of D-2 partial agonists of varying intrinsic activity levels. These agents should be of therapeutic value in treating disorders resulting from hypo-and hyperdopaminergic activity, without the side effects associated with complete D-2 agonism or antagonism.

  DOI：

  10.1021/jm9703653
• 作为产物：
  描述：

  ethyl 7-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate 在 三乙基硅烷 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以59%的产率得到7-methoxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D₂ Agonist Pharmacophore. Structure−Activity Relationships of a Series of 2-(Aminomethyl)chromans

  摘要：

  A series of 2-(aminomethyl)chromans (2-AMCs) was synthesized and evaluated for their affinity and selectivity for both the high-and low-affinity agonist states (D-2(High) and D-2(Low), respectively) of the dopamine (DA) D-2 receptor. The 7-hydroxy-2-(aminomethyl)chroman moiety was observed to be the primary D-2 agonist pharmacophore. The 2-methylchroman moiety was discovered to be an entirely novel scaffold which could be used to access the D-2 agonist pharmacophore. Attaching various simple alkyl and arylalkyl side chains to the 7-hydroxy 2-AMC nucleus had significant effects on selectivity for the D-2(High) receptor vs the 5HT(1A) and alpha(1) receptors. A novel DA partial agonist, (R)-(-)-2-(benzylamino)methyl)chroman-7-ol [R-(-)-35c], was identified as having the highest affinity and best selectivity for the D-2(High) receptor vs the alpha(1) and 5HT(1A) receptors. Several regions of the 2-AMC nucleus were modified and recognized as potential sites to modulate the level of intrinsic activity. The global minimum conformer of the 7-hydroxy-2-AMC moiety was identified as fulfilling the McDermed model D-2 agonist pharmacophoric criteria and was proposed as the D-2 receptor-bound conformation. Structure-activity relationships gained from these studies have aided in the synthesis of D-2 partial agonists of varying intrinsic activity levels. These agents should be of therapeutic value in treating disorders resulting from hypo-and hyperdopaminergic activity, without the side effects associated with complete D-2 agonism or antagonism.

  DOI：

  10.1021/jm9703653

文献信息

• Hydropyridine derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US04833169A1

  公开（公告）日：1989-05-23

  Hydropyridine derivatives of the formula ##STR1## in which R.sub.1 represents carboxy, lower alkoxycarbonyl, carbamoyl, N-lower alkylcarbamoyl or N,N-di-lower alkylcarbamoyl, R.sub.2 represents hydrogen, an optionally etherified or acylated hydroxy group or an optionally acylated amino group, and R.sub.3 represents a radical of the formula R-- (Ia), R--alk.sub.1 -- (Ib) or R'.dbd.alk.sub.2 -- (Ic) in which R represents a benzocycloalkenyl radical having a total of from 8 to 12 ring carbon atoms which is bonded via a saturated carbon atom and which is unsubstituted or is mono- or poly-substituted in the benzo moiety by hydroxy, lower alkoxy, lower alkanoyloxy, halogen, lower alkyl and/or by trifluoromethyl, and/or subsituted in the .alpha.-position by lower alkyl, and R' represents a benzocycloalkylidene radical having a total of from 8 to 12 ring carbon atoms which is unsubstituted or is mono- or poly-substituted in the benzo moiety by hydroxy, lower alkoxy, lower alkanoyloxy, halogen, lower alkyl and/or by trifluoromethyl, and alk.sub.1 represents lower alkylene or lower alkylidene and alk.sub.2 represents lower alkyl-.omega.-ylidene, wherein the dotted line is intended to show that there may be a single bond or especially a double bond, and 3-aminopropionic acid compounds of the formula R.sub.3 --NH--CH.sub.2 CH.sub.2 --R.sub.1 (IVc) in which R.sub.1 and R.sub.3 have the meanings given above, and their pharmaceutically acceptable salts, have nootropic properties and can be used as nootropic active ingredients in medicaments. They are manufactured by methods known per se.

  公式为##STR1##的吡啶衍生物，其中R.sub.1代表羧基、较低的烷氧羰基、氨基甲酰、N-较低烷基氨基甲酰或N,N-二较低烷基氨基甲酰，R.sub.2代表氢、可选择乙酰化或酰化的羟基或可选择酰化的氨基，R.sub.3代表公式R--（Ia）、R--alk.sub.1 --（Ib）或R'.dbd.alk.sub.2 --（Ic）的基团，其中R代表具有总共8至12个环碳原子的苯并环己烯基基团，通过饱和碳原子连接，并且在苯环上未被取代或者在苯基上被羟基、较低烷氧基、较低烷酰氧基、卤素、较低烷基和/或三氟甲基单取代或多取代，或者在α-位置被较低烷基取代；R'代表具有总共8至12个环碳原子的苯并环己基亚甲基基团，未被取代或者在苯基上被羟基、较低烷氧基、较低烷酰氧基、卤素、较低烷基和/或三氟甲基单取代或多取代，alk.sub.1代表较低烷基或较低烷基亚甲基，alk.sub.2代表较低烷基-ω-亚甲基，其中虚线表示可能存在单键或特别是双键，以及公式为R.sub.3 --NH--CH.sub.2 CH.sub.2 --R.sub.1（IVc）的3-氨基丙酸化合物，其中R.sub.1和R.sub.3具有上述给定的含义，及其药学上可接受的盐，具有智力增强作用，可用作药物中的智力增强活性成分。它们通过已知方法制造。
• RADIOLABELED COMPOUNDS AND METHODS THEREOF
  申请人：Newington Ian Martin

  公开号：US20130064770A1

  公开（公告）日：2013-03-14

  The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.

  本发明涉及放射性诊断化合物、制备这些化合物的方法以及将其用作成像剂的方法，优选地用于PET或SPECT，特别是HA 5-HT1A受体，其中包括成像有效量的放射性标记化合物的组合物。本发明还涉及非放射性标记化合物、制备这些化合物的方法以及将其用于治疗各种神经和/或精神障碍的方法。
• US4833169A
  申请人：——

  公开号：US4833169A

  公开（公告）日：1989-05-23
• US4939160A
  申请人：——

  公开号：US4939160A

  公开（公告）日：1990-07-03
• US5130339A
  申请人：——

  公开号：US5130339A

  公开（公告）日：1992-07-14